Aranesp (Darbepoetin Alfa)

Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) widely used for the treatment of anemia due to:
Chronic Kidney Disease (CKD) in patients who are on dialysis and patients who are not on dialysis
The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy.

Limitations of Use: This therapeutic drug has not been shown to improve quality of life (QoL), fatigue, or patient well-being.

Aranesp is not indicated for use in patients with cancer receiving hormonal agents, biologic products, or radiotherapy unless they are also receiving concomitant myelosuppressive chemotherapy; in patients undergoing myelosuppressive chemotherapy when the anticipated outcome is a cure; in patients receiving myelosuppressive chemotherapy where anemia can be managed by transfusion; and as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Recommended Dosage:
Recommended Starting Dose for Patients with CKD on Dialysis: The recommended dosage of Aranesp is 0.45 mcg/kg intravenously or subcutaneously weekly, or 0.75 mcg/kg intravenously or subcutaneously every 2 weeks. The intravenous (IV) route is recommended for patients on hemodialysis.
Recommended Starting Dose for Patients with CKD Not On Dialysis: The recommended dosage of Aranesp is 0.45 mcg/kg intravenously or subcutaneously at 4-week intervals.
Recommended Starting Dose for Pediatric Patients with CKD: The recommended dosage is 0.45 mcg/kg intravenously or subcutaneously weekly. Patients with CKD who are not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks.
Recommended Starting Dose for Patients with Cancer On Chemotherapy: The recommended dosage is 2.25 mcg/kg subcutaneously weekly, or 500 mcg subcutaneously every 3 weeks.

• With great care, it is necessary to notice that Aranesp may increase the blood clotting risk and the risk of death arising from heart attacks or strokes. It is recommended to administer the lowest effective dosage. To monitor regularly the patients suffering from heart disease or clotting problems, the clinically effective dose has to be closely supervised. It is critical to avoid exceeding the recommended hemoglobin concentration to safely reduce cardiovascular complications.
• It is highly suggested to avoid this therapy in patients with advanced cancers because it may promote tumor growth and cause rapid death in cancer patients. While avoiding chemotherapy is foremost in patients whose day-to-day living is affected by anemia symptoms, the use of this drug is recommended to enable an active life. Keeping close supervision at hemoglobin levels and not allowing it to be increased excessively is vital to ensure positive outcomes.
• Progressive high blood pressure can be a result of Aranesp plus the pre-existing kidney complications which must be taken into consideration. Hypertensive patients need regular monitoring of blood pressure to check if the control is optimal and if the dosage of anti-hypertensive drugs is satisfactory. If hypertension is left uncontrolled then Aranesp must be stopped and the dosage lowered.
• Specifically in the initiating phase of treatment with this medicinal product, patients have a strong risk of suffering from a seizure. Sudden behavior change, loss of consciousness, and confusion are major telltale signs to be kept under watch. Patients who previously had seizure problems must be handled with extreme care while giving therapy.
• Some patients may not respond to this therapy or may lose it over time. Causes could range from iron deficiency, and infections, to problems within the bone marrow. Analyze for conditions if there's no rise in hemoglobin levels and change the treatment if necessary.
• A state when Aranesp is prescribed results in a rare yet severe complication where bone marrow ceases the production of red blood cells. If there is severe anemia occurring, Aranesp must be confirmed as the suspicious factor for PRCA and if there’s a chance of it leading to such conditions needs to be removed.
• May cause symptoms as severe as allergic reactions leading to death. Symptoms turn out to be a swollen body, intense difficulty in breathing, or rashes. Medications need to be stopped and should not be taken by individuals who suffer from hypersensitivity. Need to observe them on the first dose closely.
• Symptoms like Stevens-Johnson syndrome along with toxic epidermal necrolysis could turn severe in response to taking Darbepoetin alfa. Any case of burning, peeling skin along with the wider spreading of rashes requires immediate discontinuation of the usage to avoid such frightening signs.
• People suffering from either diabetes or advanced heart failure are already in the risk category. Using this therapy with them can increase the chances of blood pressure and exacerbations in vascular access thrombosis while on dialysis. Such patients require intense following of hemoglobin and careful adjustment of the amount used to reduce anemia.
• Darbepoetin alfa should be used in pregnancy only if needed, as it may harm the baby. Breastfeeding while on this therapeutic drug is not recommended due to unknown risks. Discuss alternative treatment options with a healthcare provider.

What documents are required to import ARANESP to India?

ARANESP (darbepoetin alfa) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is ARANESP available in India?

ARANESP (Darbepoetin Alfa injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Aranesp in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

ARANESP can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ARANESP (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Aranesp injection prices in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source ARANESP (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Aranesp®?

Darbepoetin Alfa is a Generic Name for the trade name drug Aranesp®.

What is the Manufacturer's Name of Aranesp®?

Aranesp® is manufactured by Amgen Inc.

Is Aranesp approved by the FDA?

Yes, Aranesp® is approved by the FDA. Date of first approval: September 17, 2001.

What is the dosage and form of Aranesp® supplied?

Aranesp is supplied in single-dose vials: 25 mcg, 40 mcg, 60 mcg, 100 mcg, and 200 mcg and Single-dose prefilled syringes: 10 mcg/0.4 mL, 25 mcg/0.42 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL, 100 mcg/0.5 mL, 150 mcg/0.3 mL, 200 mcg/0.4 mL, 300 mcg/0.6 mL, and 500 mcg/1 mL for intravenous or subcutaneous use.

What are the most common side effects of Aranesp® injections?

The most common side effects of Aranesp® in patients with CKD are hypertension, peripheral edema, cough, dyspnea, and procedural hypotension. Side effects in patients with cancer receiving chemotherapy are abdominal pain, edema, and thrombovascular events.

How much does Aranesp® injection cost in India?

Prices of Aranesp injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Aranesp injection cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Aranesp® injections be available in SAARC countries?

Apart from Gulf countries, Aranesp® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Aranesp® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Aranesp® injections online in India?

Yes, one can buy Aranesp online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Aranesp® injections through legal channels.

What are the storage conditions of Aranesp® injections?

Store the vials at 36 to 46°F (2 to 8°C). Do not freeze. Do not shake. Protect from light; store it in the carton until use. Do not use the vial that has been shaken or frozen.